Corporate Information – Page 36 – Alligator Bioscience

2018-04-17

Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation

Lund, Sweden, 17 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-04-05

Lund, Sweden, 5 April – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals fo ...

2018-03-22

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2018-02-12

Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 16 February 2018, at 08:00 am CET, Alligator Bioscience will publish its report fo ...

2018-01-25

Lund, Sweden, 25 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-01-18

Lund, Sweden, 18 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-01-04

Lund, Sweden, 4 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunother ...

2018-01-03

Regulatory

Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-12-04

Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...